In a somewhat surprising announcement, Teva Pharmaceuticals — best known as the world’s largest manufacturer and marketer of generic drugs — has acquired the global development and marketing rights to OGX-011 from OncoGenex.
Teva has built a successful group that (to date) has focused on the development of innovative drugs for the treatment of neurological disorders — most visibly through the global marketing of glatiramer acetate (Copaxone) for multiple sclerosis and rasagiline (Azilect) for Parkinson’s disease. However, the company has had research interests in oncology for a while, and the in-licensing of OGX-011 may be a means to jump-start the development of an oncology marketing group.
As regular readers will know, OGX-011 is currently expected to enter Phase III clinical trials, in comjunction wsith docetaxel (Taxotere) for the treatment of men with castration-resistant prostate cancer (CRPC). Data available to date suggest that OGX-011 has significant potential for treatment of these men — even for those who have progressed after a first round of docetaxel-based chemotherapy.
Filed under: Drugs in development | Tagged: OGX-011, OncoGenex, Teva |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply